Physiotherapy - Based Measures (HINE, CHOP INTEND, HMFSE) for People with SMA and how they are used to Monitor Treatment Outcomes
02 September 2019 / Posted in: Treatments & Research
In this new article, our Clinical Care Research Correspondent, Dr Alex Murphy, summarises: the way some of the more commonly used physiotherapy-based outcome measures in SMA work; the research that shows how these measures would be expected to progress for those with SMA who have not accessed drug treatments.
02 September 2019 / Posted in: Information, Support
We’re delighted to announce the launch of this brand-new section of our website. It builds on knowledge and advice from the SMA Community and SMA UK’s Support Services Team, and covers a whole host of topics. If you have tips, stories and photos you’d like us to add, please do get in touch and share your experiences.
28 August 2019 / Posted in: Information
We're in the process of trying to find new accessible venues for all our events, so if you know of any that we can check out, please do let us know. Find out more here about the sort of venue / facilities we need.
13 August 2019 / Posted in: Information
ITV1's garden makeover show 'Love Your Garden with Alan Titchmarsh' is back in Autumn 2019. They're looking for families / individuals to apply or nominate someone who could benefit. Closing date 30th September.
08 August 2019 / Posted in: Treatments & Research
Thanks to all who responded to our survey asking for your views on access to Zolgensma for infants with SMA Type 1. We've passed them on to MDUK & TreatSMA and used them in our joint submission with MDUK. Click here to see the results and our submission to NICE.
07 August 2019 / Posted in: Treatments & Research
SMA UK, MDUK and TreatSMA jointly asked Biogen a number of questions relating to access to the nusinersen Managed Access Agreement with NHS England, and access in the UK in general.
Potential SMA Treatment Granted Orphan Medicinal Product Designation By The European Medicines Agency (EMA)
31 July 2019 / Posted in: Treatments & Research
Cytokinetics announced that EMA has granted Orphan Medicinal Product Designation to reldesemtiv for the potential treatment of SMA. Reldesemtiv is a drug that has been shown, in the laboratory, to increase the force generated by skeletal muscle and delay the onset and extent of muscle fatigue.
24 July 2019 / Posted in: Treatments & Research
As there have been no appeals, access to the treatment will be as outlined in the Managed Access Agreement. We have not forgotten those who don't currently have access and will continue to work to change this.
19 July 2019 / Posted in: Treatments & Research
The conference will be held at Génocentre in Evry, south of Paris between 5th & 7th February 2020 and is open for healthcare professionals and researchers in SMA to attend. The congress will feature a series of talks and workshops covering key scientific and clinical research fields in SMA.
18 July 2019 / Posted in: Information, Support
The National Children’s Bureau are carrying out a survey about people’s experience of using SEND information, advice and support services. Your answers to the questions will help the Government understand how good the services are.